The ascendancy of Viagra and its effect on the pharmaceutical landscape presents a complex question for shareholders. While the first sales statistics were astounding, the patent has lapsed, leading to a flood of off-brand alternatives that are chipping away at earnings. Moreover, the industry is facing challenges related to population trends and s